Abstract: Methods and systems for providing a personalized cannabinoid or psychedelic compound treatment regimen to a patient include obtaining genotypes of single nucleotide polymorphisms (SNPs) from a patient's genetic test and modifying base values, such as base dosages or base ratios, using weighting values reflecting the obtained genotypes to obtain regimen values for treating the patient. The regimen values take into account expected responses to cannabinoids or psychedelic compounds based on patient genetic information.